Inhaled mRNA therapy hopes to improve lung function in cystic fibrosis
NCT ID NCT07485543
First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-phase study tests an inhaled mRNA drug (BMD003) in 24 Chinese patients aged 12 and older with cystic fibrosis. The goal is to see if it is safe and can improve lung function. Participants will receive multiple doses and be monitored for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.